
|Videos|June 30, 2017
Long-Term Data Confirm TH Benefit in Early HER2-Positive Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Advertisement
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses 7-year follow-up data of the APT trial, which studied adjuvant paclitaxel/trastuzumab (TH) in early-stage patients with node-negative, HER2-positive breast cancer.
Tolaney presented the study results (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Brexucabtagene Autoleucel in Adult R/R MCL
2
Discussing a Phase 2 Defactinib/Avutometinib Trial in Diffuse Gastric Cancer
3
Anbenitamab Injection Combo Meets pCR End Point in HER2+ Breast Cancer
4
Highlighting Emerging Genitourinary Cancer Research at Columbia University
5






















































